K Pro

K Pro is an AI agent for biology developed by Owkin, designed to support smarter decision-making across the biopharma pipeline. Powered by multimodal patient data — including genomic, transcriptomic, spatial, and clinical data — K Pro enables drug discovery and development teams to ask questions in natural language and receive rigorous, publication-ready answers. It continuously learns from real-world data, user feedback, and clinical validation, positioning itself as the first agent to connect research to clinical care.

K Pro is built for biopharma researchers, portfolio strategists, and clinical development teams who need to move efficiently from early target discovery through to clinical trial enrichment. Its flexible architecture is designed to tackle a wide range of pipeline challenges, including early portfolio decisions, population and indication selection, and clinical trial data enrichment with real-world insights.

Core Capabilities

• Prioritize targets: Rank therapeutic targets and gene candidates using statistical evidence drawn from TCGA and MOSAIC datasets.
• Assess druggability: Evaluate target tractability, safety profiles, and therapeutic potential using curated databases.
• Characterize patient subgroups: Identify distinct patient populations based on multi-omics profiles and clinical outcomes.
• Generate comprehensive reports: Create publication-ready statistical reports covering gene and target assessment, biomarker prioritization, and patent landscape analysis.
• Validate biomarkers across modalities: Test biomarkers and hypotheses across bulk RNA-seq, single-cell, spatial, and clinical data.
• Connect biology to clinical outcomes: Integrate genomic, transcriptomic, and immune data to identify therapeutic opportunities and predict treatment response.

Intelligent Orchestration

• K Pro uses a single intelligent orchestrator that dynamically selects and combines specialized AI skills to address challenges across drug discovery and development.
• Rather than requiring users to manage multiple tools, K Pro activates the right capabilities automatically based on the task at hand.
• Its flexible architecture means it can address both anticipated and novel pipeline challenges.

Key Differentiators

• A decade of pharma AI expertise: Ten years of proven AI drug discovery knowledge, purpose-built for biopharma pipelines.
• Research-to-care intelligence: AI insights validated by real patients, bridging the gap between discovery and clinical reality.
• Multimodal patient data: Grounded in real-world, deeply differentiated patient datasets including the full MOSAIC spatial and multi-omics dataset.
• Secure, interpretable, and interoperable: A compliant and transparent platform built to integrate with existing infrastructure.
• Continuous learning: The agent evolves with every trial, experiment, and patient outcome.

Use Cases

• Early portfolio decisions: Assess drug and program opportunities with confidence using decision-grade analysis.
• Population and indication decisions: Define the right patient populations and predictive biomarkers before a trial begins.
• Clinical trial decisions: Enrich early clinical trial data with real-world insights to improve trial design and outcomes.

Pricing and Access Tiers

• Free tier: Access to 19 public datasets and a MOSAIC subset of 60 samples, with limited usage and standard support, available via SaaS only.
• Professional tier: Includes everything in the free tier plus access to Owkin proprietary datasets and the full MOSAIC spatial and multi-omics dataset, high usage limits, untracked privacy, dedicated onboarding and account management, and the option for SaaS or on-premise/client-instance deployment.

K Pro is trusted by leading academic medical centers and biopharma institutions, with endorsements from researchers at APHP, Institut Gustave Roussy, and University College London. The platform is deployable as a SaaS solution or on client premises, and is built with compliance, transparency, and interoperability at its core — making it suitable for organizations with stringent data governance requirements.